Objective: To assess the effectiveness of osteopathic intervention (OI) and general osteopathic treatment (GOT) in individuals with fibromyalgia syndrome (FMS). Methods: The trial was designed as a randomized controlled trial with 2 osteopathic interventions and 1 untreated control group. The patients in the two osteopathic groups received 10 osteopathic treatments (OI or GOT) within a time period of 12 weeks. The control group did not receive any osteopathic treatment. The primary outcome was the average pain intensity (API) assessed by visual analog scale (VAS). Secondary outcomes were the pressure-pain threshold rated by means of a tender point score, and disease severity, assessed by the Fibromyalgia Impact Questionnaire (FIQ). Results: 50 patients were randomized. The primary outcome parameter API decreased from 7.2 to 4.7 in the OI group, from 6.3 to 4.3 in the GOT group, and increased slightly in the control group from 6.2 to 6.6. There were significant differences for the change in API between the OI group and the control group (VAS: 2.9, 95% confidence interval (CI) = 1.12-4.52), and between the GOT group and the control group (VAS: 2.4, 95% CI = 0.65-4.11), but no significant differences between the OI group and the GOT group. There were no significant differences for the secondary outcome parameters between the groups. Conclusion: A series of osteopathic treatments might be beneficial for patients suffering from FMS.

Keywords:
Osteopathy, Fibromyalgia, Randomized, Clinical trial, Effectiveness
1.
Jacobsen S, Danneskiold-Samsoe B, Lund B: Consensus document on fibromyalgia: the Copenhagen Declaration. J Musculoskelet Pain 1993;1:295-312.
2.
Wolfe F, Smythe HA, Yunus MB, et al: The American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172.
3.
Wolfe F, Clauw DJ, Fitzcharles MA, et al: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-610.
4.
Bannwarth B, Blotman F, Lay KR, et al: Fibromyalgia syndrome in the general population of France. A prevalence study. Joint Bone Spine 2009;76:184-187.
5.
Bennett RM, Jones J, Turk DC, et al: An Internet survey of 2596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:11.
6.
Macfarlane GJ, Thomas E, Papageorgiou AC, et al: The natural history of chronic pain in the community: a better prognosis than in the clinic? J Rheumatol 1996;23:1617-1620.
7.
White KP, Speechley M, Harth M, et al: Fibromyalgia in rheumatology practice: a survey of Canadian rheumatologists. J Rheumatol 1995;22:722-726.
8.
Henningsen P, Zimmermann T, Sattel H: Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003;65:528-533.
9.
Van Houdenhove B, Luyten P: Stress, depression and fibromyalgia. Acta Neurol Belg 2006;106:149-156.
10.
Boonen A, van den Heuvel R, van Tubergen A, et al: Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;64:396-402.
11.
Henriksson CM, Liedberg GM, Gerdle B: Women with fibromyalgia: work and rehabilitation. Disabil Rehab 2005;27:685-694.
12.
Penrod JR, Bernatsky S, Adam V, et al: Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004;31:1391-1398.
13.
Goldenberg DL, Burckhardt C, Crofford L: Management of fibromyalgia syndrome. JAMA 2004;292:2388-2395.
14.
Eisenberg DM, Davis RB, Ettner SL, et al: Trends in alternative medicine use in the United States; 1990-1997. JAMA 1998;280:1569-1575.
15.
White LA, Birnbaum HG, Kaltenboeck A, et al: Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24.
16.
Lind BK, Lafferty WE, Tyree PT, et al: Use of complementary and alternative medicine providers by fibromyalgia patients under insurance coverage. Arthritis Rheum 2007;57:71-76.
17.
Callahan LF, Wiley-Exley EK, Mielenz TJ, et al: Use of complementary and alternative medicine among patients with arthritis. Prev Chronic Dis 2009;6:A44.
18.
Schneider MJ, Vernon H, Ko G, et al: Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. J Manipulative Physiol Ther 2009;32:25-40.
19.
Ernst E: Chiropractic treatment for fibromyalgia: a systematic review. Clin Rheumatol 2009;28:1175-1178.
20.
Terhorst L, Schneider MJ, Kim KH, et al: Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. J Manipulative Physiol Ther 2011;34:483-496.
21.
Gamber RG, Shores JH, Russo DP, et al: Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome: results of a randomized clinical pilot project. J Am Osteopath Assoc 2002;102:321-325.
22.
World Medical Association: World Medical Association Declaration of Helsinki. JAMA 2013;310:2191-2194.
23.
Collins SL, Moore RA, McQuay HJ: The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997;72:95-97.
24.
Jäckel WH: Fibromyalgie. Z Rheumatol 2007;66:579-590.
25.
Goldenberg DL: Diagnosis and differential diagnosis of fibromyalgia. Am J Med 2009;122:12-21.
26.
Wendler J: Schmerzmessung in der Rheumatologie. Aktuelle Rheumatol 2010;35:172-177.
27.
Schomacher J: Gütekriterien der visuellen Analogskala zur Schmerzbewertung. Physio-Science 2008;4:125-133.
28.
Burckhardt CS, Clark SR, Bennett RM: The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-733.
29.
Offenbächer M, Waltz M, Schoeps P: Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G). J Rheumatol 2000;27:1984-1988.
30.
AACOM (American Association of Colleges of Osteopathic Medicine): Glossary of osteopathic terminology. www.aacom.org/docs/default-source/insideome/got2011ed.pdf?sfvrsn=2, 2009 (last accessed January 7, 2017)
31.
WHO (World Health Organization): Benchmarks for training in osteopathy. http://apps.who.int/medicinedocs/ documents/s17555en/s17555en.pdf, 2010 (last accessed January 7, 2017).
32.
OIA (Osteopathic International Alliance): Osteopathy and osteopathic medicine. A global view of practice, patients, education and the contribution to healthcare delivery. http://oialliance.org/resources/oia-status-report/, 2014 (last accessed January 7, 2017).
33.
Faul F, Erdfelder E, Lang AG, et al: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-191.
34.
Heinrich-Heine-Universität Düsseldorf: G*Power: statistical power analyses for Windows and Mac. www.gpower.hhu.de/en.html (last accessed January 7, 2017).
35.
Matáran-Peñarrocha GA, Castro-Sánchez AM, Carballo García G, et al: Influence of craniosacral therapy on anxiety, depression and quality of life in patients with fibromyalgia. Evid Based Complement Alternat Med 2011;2011:178769.
36.
Castro-Sánchez AM, Matarán-Peñarrocha GA, Arroyo-Morales M, et al: Effects of myofascial release techniques on pain, physical function, and postural stability in patients with fibromyalgia: a randomized controlled trial. Clin Rehabil 2011;25:800-813.
37.
Hilfiker R: Assessments: visuelle Analog- und numerische Ratingskala - die Schmerzintensität messen. Ergopraxis 2010;3:26-27.
38.
Cepeda MS, Africano JM, Polo R, et al: What decline in pain intensity is meaningful to patients with acute pain? Pain 2003;105:151-157.
39.
Gleich A, Klein Ch, Saleem S: Die Auswirkungen von osteopathischen Behandlungen bei Patientinnen mit dem Fibromyalgiesyndrom. Eine zweiphasige Prä-Post-Studie. München, College Sutherland/Osteopathische Akademie, 2011 (unpublished).
40.
Castro-Sánchez AM, Matarán-Peñarrocha GA, Sánchez-Labraca, et al: A randomized controlled trial investigating the effects of craniosacral therapy on pain and heart rate variability in fibromyalgia patients. Clin Rehabil 2011;25:25-35.
41.
Bennett RM, Bushmakin AG, Cappelleri JC, et al: Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009;36:1304-1311.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.